Category - Developments

Eiger BioPharmaceuticals (NASDAQ:EIGR) completed enrollment of the Phase 2 ULTRA study designed to evaluate the effects of ubenimex in patients with primary and secondary lymphedema of the lower limbs. A total of 54...

Ortho Regenerative Technologies (CSE:ORTH.CN) announced that a peer-reviewed article entitled, “Freeze-Dried [Ortho-R] Injectable Surgical Implants for Meniscus Repair: Pilot Feasibility Studies in Ovine...

IntelGenx (OTCQX:IGXT; TSXV:IGX) announced that its plant, following a Good Manufacturing Practices (GMP) inspection performed by Health Canada, has obtained an amended Drug Establishment License (DEL) for manufacturing...

Health Canada has cleared IntelGenx’s (OTCQX:IGXT; TSXV:IGX) clinical trial application for its Montelukast VersaFilm intended for the treatment of mild-to-moderate Alzheimer’s disease (AD). The phase 2a proof-of...

Hutchison China MediTech (AIM, NASDAQ:HCM) has initiated a U.S. Phase 1 bridging clinical trial of fruquintinib, a highly selective and potent oral inhibitor of vascular endothelial growth factor receptors 1, 2 and 3...

3D Signatures’ (TSXV:DXD; OTCQB:TDSGF; FSE:3D0) non-brokered private placement has been fully subscribed for and has closed for gross proceeds of $1,622,673. The private placement involved the sale of 8,113,365 units at...

The U.S. Patent and Trademark Office granted a notice of allowance to IntelGenx (OTCQX:IGXT; TSXV:IGX) for a patent entitled, “Device and Method of Treating Conditions Associated with Neuroinflammation.” The...

Vital Therapies (NASDAQ:VTL) has been selected for addition to the NASDAQ biotechnology index, effective prior to the opening on Dec. 18. Companies in the index must meet eligibility requirements, including minimum...

A peer-reviewed article published in the current issue of Biomedical Materials has provided further validation that Ortho Regenerative Technologies’ (CSE:ORTH) Ortho-R hybrid implants release more growth factors and...

Closely-held NeuroproteXeon announced the publication of a second finding from a randomized, controlled Phase 2 trial of inhaled xenon and oxygen, combined with hypothermia, for out-of-hospital cardiac arrest (OHCA)...